AHCC (Active Hexose Correlated Compound) is a proprietary extract derived from the mycelia of shiitake mushrooms and other related species. Its use for supporting infection is primarily based on scientific investigation, though the evidence is limited and largely preclinical or from small clinical studies.

Several animal studies and in vitro experiments suggest that AHCC may enhance immune responses, including increasing natural killer (NK) cell activity, dendritic cell numbers, and cytokine production. These immune-modulating actions are thought to potentially help the body respond more effectively to infections. In a few small human trials, AHCC supplementation has been associated with improved immune parameters in healthy volunteers and in some patient populations, such as those undergoing chemotherapy. There is also limited clinical research suggesting potential benefit in reducing the duration or severity of certain viral infections, such as influenza and human papillomavirus (HPV), though these studies are generally small, non-blinded, or lack rigorous controls.

Overall, while AHCC shows promise as an immune modulator that might support the body’s response to infections, robust clinical evidence demonstrating direct efficacy against infections is lacking. Larger, well-designed human studies are needed to confirm whether AHCC can reliably support or treat infections. Current use is better characterized as adjunctive support rather than a primary treatment for infections.